Survodutide
Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
0.6 – 4.8 mg
0.6 mg
Initiation, part of a 20-week up-titration
3.6 mg
26-week maintenance after escalation
4.8 mg
26-week maintenance after escalation
Compound profile
Scientific & efficacy data
Weight Management
Peptide profile
Strong human trials
Survodutide
0.6 mg · Once daily
Molecular formula
C192H289N47O61
- Mol. weight
- 4,231.6 Da
- CAS number
- 2805997-46-8
- PubChem
- 168429725
- Developed · Phase 3 ongoing (2023-present)
- Roche / Carmot Therapeutics
Roche / Carmot Therapeutics (Novo Nordisk partnership)
Amino acid sequence
Modified GLP-1/Glucagon-analogue fusionWeight Management
Up to 14.9% weight loss at 46 weeks through dual GLP-1R and GCGR activation — enhancing both appetite suppression and energy expenditure beyond GLP-1 alone
Metabolic Health
62% MASH resolution rate at optimal dose, significant hepatic fat reduction, and comprehensive metabolic improvements including glycemic control and lipid profiles
Blood Sugar Control
HbA1c reductions up to 1.71% in type 2 diabetes with greater weight loss than semaglutide at equivalent glycemic efficacy
Dosing
How much do I take?
0.6 mg, titrated to 4.8 mg · once weekly
0.6 – 4.8 mg
Once weekly
Covers all 3 documented dose levels · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for significant body weight reduction in obesity & mash/nash resolution and liver fibrosis improvement
Best for
Significant body weight reduction in obesity
Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
MASH/NASH resolution and liver fibrosis improvement
Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Type 2 diabetes management with concurrent weight loss goals
Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhanced metabolic outcomes through dual receptor engagement
Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Survodutide with similar peptides to find the best fit for your goals.
Administration
How do I use it?
subcutaneous injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (nausea up to 75% at highest doses, diarrhea, vomiting) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure.
Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential.
Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.
Phase 2 trial safety data in ~400 patients supports tolerability for up to 48 weeks, though long-term data beyond 1 year remains limited prior to potential regulatory approval. Cardiovascular outcome trials and long-term hepatic safety monitoring in MASH population are ongoing.
Not yet FDA-approved—all use remains investigational pending Phase 3 completion.
Common side effects · experienced by some users
Nausea
The most frequently reported adverse event, occurring in up to 75% of survodutide-treated patients versus 42% on placebo. Dose-dependent and most pronounced during dose escalation. Odds ratio increases from 6.11 at 2.4 mg to 27.54 at 4.8 mg.
Management: Gradual dose escalation over 16-20 weeks significantly reduces nausea incidence and severity. Smaller meals, avoiding high-fat foods, and adequate hydration help. Symptoms typically diminish with continued treatment.
Vomiting
Frequently accompanies nausea during dose escalation. Dose-dependent occurrence related to dual GLP-1R and GCGR activation in the gastrointestinal tract and central nervous system.
Management: Slower dose titration. Anti-emetics if needed. Ensure hydration. May temporarily hold dose escalation if severe.
Diarrhea
Gastrointestinal disturbance from combined receptor activation affecting gut motility and secretion. Generally mild to moderate severity.
Management: Maintain hydration. Usually resolves with continued treatment. Dose adjustment if persistent.
Decreased Appetite
Expected pharmacological effect contributing to weight loss. Mediated through both GLP-1R and GCGR central nervous system effects on appetite regulation.
Management: Generally beneficial for the treatment goal. Ensure adequate nutritional intake despite reduced appetite. Monitor for excessive caloric restriction.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Survodutide
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Survodutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Metformin — Complementary insulin-sensitizing mechanism with established cardiovascular benefits supports comprehensive metabolic management
- Safe:SGLT2 Inhibitors — Independent glucose-lowering and cardiorenal protective mechanisms complement survodutide's metabolic and hepatic benefits
- Safe:Dietary Intervention — Caloric restriction synergizes with survodutide's appetite suppression and enhanced energy expenditure for maximal weight loss
With medications
- Caution:Other GLP-1 Receptor Agonists — Redundant GLP-1R activation with no additional benefit and increased gastrointestinal adverse events
- Caution:Insulin Secretagogues — Increased hypoglycemia risk when combined with agents that stimulate insulin secretion independent of glucose levels
- Caution:Glucagon for Hypoglycemia Rescue — Survodutide's glucagon receptor agonism may alter the pharmacodynamics of exogenous glucagon used in hypoglycemia emergencies
With supplements
- Safe:Multivitamins — Generally safe to take alongside Survodutide. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Strong human trials · first signs weeks 1-16
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
Survodutide is a dual GLP-1/glucagon receptor agonist designed to deliver even stronger weight loss and metabolic benefits than single-hormone drugs by activating two appetite and metabolism control pathways simultaneously.
The deeper mechanism
Survodutide is a potent dual GLP-1/glucagon receptor agonist engineered to activate both the GLP-1 receptor (promoting insulin secretion and appetite suppression) and the glucagon receptor (promoting energy expenditure and hepatic glucose metabolism).
The dual activation amplifies weight loss through complementary mechanisms: GLP-1 suppresses appetite and slows gastric emptying while glucagon increases energy expenditure, elevates metabolic rate through activation of brown adipose tissue thermogenesis, and promotes hepatic fat oxidation—collectively producing synergistic metabolic improvements exceeding single-hormone agonists.
What to expect
Weeks 1-16
What you might notice
- Dose escalation period with gradual introduction
- GI side effects (nausea, vomiting) are most common during this phase
- Early appetite reduction and beginning of weight loss
What's normal
- Nausea is expected and typically peaks during dose increases
- Appetite reduction begins early
- Weight loss starts but accelerates as maintenance dose is reached
- GI symptoms generally improve with continued dosing
What's next
- Complete dose escalation to target maintenance dose (3
- 0 mg weekly)
- GI tolerability typically improves as the body adjusts to each dose level
Weeks 16-32
What you might notice
- Accelerating weight loss at maintenance dose
- Improved glycemic markers if diabetic
- GI side effects diminishing
- Measurable improvements in metabolic parameters
What's normal
- Steady weight loss trajectory
- HbA1c improvements in diabetic patients
- Liver enzyme improvements in MASH patients
- Reduced appetite stabilizes
- GI side effects become less frequent
What's next
- Continue maintenance dosing
- Clinical assessment of weight loss, metabolic parameters, and liver health markers
Weeks 32-52+
What you might notice
- Continued weight loss approaching 10-15% of body weight
- Sustained metabolic improvements
- In MASH patients, potential histological improvement on liver biopsy
What's normal
- Weight loss may continue beyond 46 weeks (Phase 2 data suggested ongoing trajectory)
- Metabolic parameters remain improved
- Weight loss rate may gradually slow as new steady state is approached
What's next
- Long-term maintenance therapy
- Phase 3 trials evaluating 76-week outcomes will define long-term efficacy and safety profile
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Survodutide over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Clinical trials
Tested in people
49 registered studies, 6 still enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 17,065 people took part in the studies that actually administered Survodutide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity
Boehringer Ingelheim
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Boehringer Ingelheim
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
Boehringer Ingelheim
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Survodutide is named as an intervention; studies that only mention it in passing are not.
Questions
Frequently asked
How does survodutide differ from semaglutide and other GLP-1 agonists?
Survodutide is a dual agonist that activates both the GLP-1 receptor AND the glucagon receptor, while semaglutide only activates the GLP-1 receptor. The glucagon receptor component adds a fundamentally different mechanism — it increases energy expenditure, stimulates hepatic fat oxidation, and promotes thermogenesis. In head-to-head Phase 2 comparison, survodutide produced greater weight loss (8.7% vs 5.3%) than semaglutide at equivalent glycemic control in type 2 diabetes patients.
What is the MASH breakthrough therapy designation?
The FDA granted survodutide Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis. This was based on Phase 2 data showing 62% of patients achieved MASH resolution without worsening fibrosis at the 4.8 mg dose, compared to only 14% with placebo. This designation accelerates the development and regulatory review process.
When might survodutide become commercially available?
Survodutide is currently in Phase 3 clinical trials. The SYNCHRONIZE obesity program and LIVERAGE MASH program are expected to report results in 2026-2027. Regulatory submissions could follow positive Phase 3 results, with potential approval estimated for 2027-2028, though timelines depend on trial outcomes and regulatory review.
Why does survodutide cause more GI side effects than some other treatments?
Survodutide stimulates both GLP-1 and glucagon receptors in the gastrointestinal tract and central nervous system, resulting in more pronounced effects on gut motility, gastric emptying, and appetite signaling compared to GLP-1-only agonists. Nausea occurred in up to 75% of patients versus 42% on placebo. However, gradual dose escalation over 16-20 weeks significantly mitigates these effects, and most patients tolerate the medication well at maintenance doses.
Is the glucagon component of survodutide safe for diabetic patients?
Yes, the glucagon receptor agonism does not worsen glycemic control because it is balanced by the GLP-1 receptor component which promotes glucose-dependent insulin secretion. In Phase 2 diabetes trials, survodutide achieved comparable HbA1c reduction to semaglutide while providing superior weight loss. The dual agonism appears metabolically synergistic rather than antagonistic.
What Phase 3 trials are currently running?
Several Phase 3 programs are underway: SYNCHRONIZE-1 (obesity without diabetes, n=726), SYNCHRONIZE-2 (obesity with T2DM, n=755), SYNCHRONIZE-CVOT (cardiovascular outcomes, n=5,531), LIVERAGE (MASH with fibrosis, n=1,800), and regional trials in China and Japan. These represent one of the largest clinical development programs for a metabolic disease agent.
Further reading
History & related research
History · since 2017
The Dual-Power Drug That Breaks the Glucagon Taboo
For decades, doctors feared glucagon — the hormone that raises blood sugar. But one team at Boehringer Ingelheim asked a revolutionary question: What if we ADDED glucagon instead of blocking it?
Read the full history of SurvodutideReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Survodutide, on one page.